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Determination of Malignant and Invasive Predictors in Branch 
Duct Type Intraductal Papillary Mucinous Neoplasms of the 
Pancreas: A Suggested Scoring Formula
Prediction of malignancy or invasiveness of branch duct type intraductal papillary 
mucinous neoplasm (Br-IPMN) is difficult, and proper treatment strategy has not been well 
established. The authors investigated the characteristics of Br-IPMN and explored its 
malignancy or invasiveness predicting factors to suggest a scoring formula for predicting 
pathologic results. From 1994 to 2008, 237 patients who were diagnosed as Br-IPMN at 11 
tertiary referral centers in Korea were retrospectively reviewed. The patients’ mean age was 
63.1 ± 9.2 yr. One hundred ninty-eight (83.5%) patients had nonmalignant IPMN (81 
adenoma, 117 borderline atypia), and 39 (16.5%) had malignant IPMN (13 carcinoma in 
situ, 26 invasive carcinoma). Cyst size and mural nodule were malignancy determining 
factors by multivariate analysis. Elevated CEA, cyst size and mural nodule were factors 
determining invasiveness by multivariate analysis. Using the regression coefficient for 
significant predictors on multivariate analysis, we constructed a malignancy-predicting 
scoring formula: 22.4 (mural nodule [0 or 1]) + 0.5 (cyst size [mm]). In invasive IPMN, the 
formula was expressed as invasiveness-predicting score = 36.6 (mural nodule [0 or 1]) + 
32.2 (elevated serum CEA [0 or 1]) + 0.6 (cyst size [mm]). Here we present a scoring 
formula for prediction of malignancy or invasiveness of Br-IPMN which can be used to 
determine a proper treatment strategy. 
Key Words: Branch Duct Type Intraductal Papillary Mucinous Neoplasm (IPMN); Cyst Size; 
Mural Nodule; CEA; Malignancy; Invasive Carcinoma
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INTRODUCTION
Intraductal papillary mucinous neoplasm (IPMN) is a tumor 
characterized by dilatation of the main pancreatic duct with mu-
cin; it has distinct malignant potential (1). In recent times, the 
clinical and pathological characteristics have been elucidated, 
and several treatment guidelines have been suggested (2-4). 
IPMNs involving the main pancreatic duct have a relatively high Hwang DW, et al.  •  Scoring Formula for Prediction of Malignant Branch Duct IPMN
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risk of progression to malignancy and invasive carcinoma, so 
International Consensus Guidelines recommend surgical resec-
tion of IPMN involving the main pancreatic duct (3-6).
  Branch duct type IPMN is known to carry a lower risk of ma-
lignancy compared to main duct IPMN. Hence, there are many 
different opinions about the necessity of surgical resection and 
the timing of surgery (4). Furthermore, controversy still exists 
with regard to when to operate and when to observe. It is certain 
that malignant IPMN, especially invasive IPMN, has poorer prog-
nosis compared to benign and non-invasive IPMN (1, 4, 7). When 
selecting a treatment for branch duct IPMN, we consider several 
factors, including tumor behavior and the patient’s condition. 
However, the most important factor affecting our treatment de-
cision may be tumor malignancy. Recently published papers 
have demonstrated similar concepts regarding branch duct type 
IPMN (4, 8, 9). In the clinical setting, these results gave us a lot 
of help in determining the surgical management, but predicting 
the risk for an individual patient was more important and valu-
able than enumerating the overall risk using statistical analysis. 
Hence, a formula for predicting the malignancy risk of an indi-
vidual patient would be greatly helpful. 
  The aims of this study were to investigate the predictors of ma-
lignant and invasive IPMN, and to construct a formula to calcu-
late the probability of malignancy and invasiveness. By using 
this method, we hoped to suggest new surgical guidelines for 
branch duct type IPMN that does not involve the main pancre-
atic duct. 
 
MATERIALS AND METHODS
Selection of enrolled centers and radiologic parameters
We retrospectively collected the data for IPMN cases registered 
between January 1994 and September 2008. Eleven tertiary med-
ical centers with specialized biliary-pancreatic surgeons, gastro-
intestinal radiologists, and gastrointestinal pathologists partici-
pated in this study.
  We designed standardized case-report forms containing fields 
for IPMN clinical, radiological, and pathological characteristics 
and survival data. A standard protocol for interpreting radiolog-
ical and pathological data was made by experienced radiologists 
and pathologists at Seoul National University Hospital. 
  For standardized radiological information, images from cross-
sectional studies (contrast-enhanced computed tomography 
[CT] and magnetic resonance imaging [MRI]) and pancreatog-
raphy (magnetic resonance cholangiopancreatography [MRCP] 
or endoscopic retrograde cholangiopancreatography [ERCP]) 
were used to classify the type of IPMN. Standardized criteria in-
cluded IPMN morphology (main, branch, or mixed), anatomic 
location of the main lesion, distribution, multifocality, presence 
of mural nodule, lesion size, septation, wall thickening, calcifi-
cation, and parenchymal atrophy. Analyses of these factors were 
based mainly on CT, and information from other imaging meth-
ods was used to support the information gained from CT. 
  Branch duct type IPMN was defined as a cystic dilatation of a 
branch pancreatic duct or a pancreatic cyst communicating with 
the pancreatic duct without main duct dilatation. The term ‘with-
out main duct dilatation’ indicated a maximal main pancreatic 
duct diameter of 5 mm or less. This was thought to be the most 
restricted and well-represented criteria for branch duct type 
IPMN (3, 5, 10-12). Main duct type IPMN was radiologically de-
fined as a main pancreatic duct dilated > 5 mm. Mixed type IPMN 
was defined as radiologic evidence of both main and branch 
duct type IPMN (3, 5, 10-12). Wall thickening was considered to 
be present when the wall was ≥ 2 mm in maximum thickness 
and covered at least one-third of the cystic lesion or the dilated 
pancreatic duct. Pancreatic parenchymal atrophy was defined 
as a situation in which the ratio of the diameter of the main pan-
creatic duct to the width of the pancreatic parenchyma at the 
same location was greater than 0.5 (12). A mural nodule was 
defined as a soft tissue nodule attached to the lesion wall, or as 
a septum in the pancreatic cystic lesion or the dilated main pan-
creatic duct. Mural nodule status only was applied in this study. 
Mural nodule size was not investigated, because CT is not the 
gold standard for measuring mural nodule size (12).
 
Study population and clinicopathological characteristics
During the above-mentioned period, a total of 388 patients pre-
operatively diagnosed with IPMN and cystic dilatation of a branch 
duct underwent surgical resection. Pathological confirmation 
was performed in all 11 medical centers. Patients with main ducts 
dilated to larger than 5 mm (n = 151) were excluded from this 
study. Thus, a total of 237 patients were eligible for this study. 
We analyzed the medical records, results of preoperative labo-
ratory and radiologic examination and postoperative patholog-
ic examination, and follow-up data. 
  The study subjects consisted of 137 men and 100 women of 
mean age 63.1 yr (range, 38-83 yr). There were 148 (62.4%) symp-
tomatic patients. Frequently manifested symptoms and signs 
included abdominal pain, weight loss, jaundice, diabetes melli-
tus, and pancreatitis. Elevated serum carcinoembryonic anti-
gen (CEA, > 5 ng/mL) was identified in 9 (3.8%) patients, and 
elevated serum carbohydrate antigen 19-9 (CA 19-9, > 37 U/mL) 
was detected in 31 (13.1%) patients. The mean cystic tumor size 
was 28.1 ± 18.0 mm. Thirty-one (13.1%) patients had mural nod-
ules on CT (Table 1). Combined extrapancreatic malignancies 
were detected in 65 (27.4%) patients. Stomach cancer was the 
most common malignancy (26 patients, 11.0%), followed by 
colorectal cancer (14 patients, 5.9%), other hepatobiliary-pan-
creatic cancer (12 patients, 5.1%), and urologic cancer (5 pati-
ents, 2.1%). Among the various operative procedures, pancre-
aticoduodenectomy (including pylorus-preserving procedures) 
was most common (108 [45.6%] patients). For limited resection, Hwang DW, et al.  •  Scoring Formula for Prediction of Malignant Branch Duct IPMN
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duodenum-preserving resection of the head of the pancreas, 
pancreatic head resection with segmental duodenectomy, me-
dian pancreatectomy, and excision were performed in 4 (1.7%), 
3 (1.3%), 12 (5.1%), and 14 (5.9%) patients, respectively. Patho-
logic examination according to the AJCC 6th edition manual 
showed malignant IPMN (carcinoma in situ or invasive IPMC) 
in 39 (16.5%) patients and invasive IPMN in 26 (11.0%) patients. 
Extrapancreatic tumor extension (pT3) was identified in 8 (30.8%) 
patients with invasive IPMN, and metastatic lymph nodes were 
identified in 3 (11.5%) patients with invasive IPMN (n = 26) (Ta-
ble 2).
Statistical analysis
Differences between categorical variables were analyzed using 
the chi-squared test and Fisher’s exact test, while the Student t-
test and Mann-Whitney U test were used for comparisons among 
continuous variables. The statistical correlation between out-
comes and categorical/continuous factors was determined us-
ing logistic regression analysis. Statistical significance was de-
fined as P < 0.05 (two-sided P values). 
  Parameters identified by univariate analysis with P < 0.05 were 
entered into multivariate analysis to identify independent ma-
lignant and invasive predicting factors.
  Receiver-operator characteristic (ROC) curves were used to 
determine optimal score cutoff levels for the prediction of ma-
lignant and invasive IPMN. All analyses were carried out using 
SPSS version 15.0 for Windows (SPSS, Chicago, IL, USA).
Table 1. Clinical and radiologic characteristics of 237 patients with branch-duct type IPMN
Parameters Total  
(n = 237)
Adenoma  
(n = 81)
Borderline atypia  
(n = 117)
Carcinoma in situ  
(n = 13)
Invasive carcinoma  
(n = 26)
Age (yr, range) 63.1 ± 9.2 (38-83) 63.0 ± 10.4 (38-82) 62.9 ± 8.7 (39-83) 63.9 ± 5.9 (53-77) 64.1 ± 8.7 (45-78)
Sex (M:F) 137:100 (1.37:1) 41:40 (1.02:1) 72:45 (1.6:1) 8:5 (1.6:1) 16:10 (1.6:1)
Symptom (%)
   Weight loss
   Jaundice
   Abdominal pain
   Diabetes mellitus
   History of pancreatitis
148 (62.4)
23 (9.7)
13 (5.5)
  80 (33.8)
  31 (13.1)
12 (5.1)
 
8 (9.8)
5 (6.2)
32 (39.5)
4 (4.9)
4 (4.9)
 
10 (8.5)
  5 (4.3)
  36 (30.8)
  17 (14.5)
  6 (5.1)
 
1 (7.7)
1 (7.7)
  5 (38.5)
  3 (23.1)
1 (7.7)
 
  4 (15.4)
2 (7.7)
  7 (26.9)
  7 (26.9)
1 (3.8)
CEA, elevated (%)*   9 (3.8) 4 (4.9)   2 (1.7) -   3 (11.5)
CA 19-9, elevated (%)
†   31 (13.1) 10 (12.3) 10 (8.5) 1 (7.7) 10 (38.5)
Radiologic tumor size (mm) 28.1 ± 18.0 22.8 ± 14.2 27.4 ± 12.8 36.8 ± 28.0 43.3 ± 30.5
Mural nodule (%)   31 (13.1) 5 (6.2)   12 (10.3) - 14 (53.8)
Location of main lesion (%)
   Head & uncinate
   Body & tail
   Diffuse
 
120 (50.6)
  87 (36.7)
  28 (11.8)
 
44 (54.3)
29 (35.8)
8 (9.9)
 
  58 (49.6)
  44 (37.6)
  13 (11.1)
 
  3 (23.1)
  7 (53.8)
  3 (23.1)
 
15 (57.7)
  7 (26.9)
  4 (15.4)
*CEA, elevated; serum concentration > 5 ng/mL; 
†CA19-9, elevated; serum concentration > 37 U/mL. 
Table 2. Operative and pathological characteristics of 237 patients with branch-duct type IPMN
Clinical findings Total  
(n = 237)
Adenoma  
(n = 81)
Borderline atypia  
(n = 117)
Carcinoma in situ  
(n = 13)
Invasive carcinoma  
(n = 26)
Operation (%)
   Whipple
   PPPD
   Total pancreatectomy
   Distal pancreatectomy
   Spleen preserving DP
   Subtotal pancreatectomy
   HPD
   Median pancreatectomy
   DPRHP
   PHRSD
   Excision 
 
  32 (13.5) 
  76 (32.1) 
  5 (2.1)
  65 (27.4) 
20 (8.4) 
  5 (2.1) 
  1 (0.4) 
12 (5.1) 
  4 (1.7) 
  3 (1.3) 
14 (5.9) 
 
10 (12.3) 
27 (33.3) 
3 (3.7)
20 (24.7) 
7 (8.6) 
1 (1.2) 
- 
2 (2.5) 
-
- 
  9 (11.1) 
 
  13 (11.1) 
  39 (33.3) 
-
  30 (25.6) 
  12 (10.3) 
  3 (2.6) 
  1 (0.9) 
10 (8.5) 
  3 (2.6) 
  3 (2.6) 
  5 (4.3) 
 
2 (15.4) 
2 (15.4) 
2 (15.4)
7 (53.8) 
-
-
-
-
-
-
-
 
  7 (26.9) 
  8 (30.8) 
-
  8 (30.8) 
1 (3.8) 
1 (3.8)
-
- 
1 (3.8)
-
-
In-hospital mortality (%)   2 (0.8)  2 (2.5)  - - -
Involvement of RM (%) 19 (8.0) 1 (1.2)   13 (11.1) 2 (15.4)   3 (11.5)
Involvement of main duct (%)   32 (13.5) 14 (17.3)   14 (12.0) 2 (15.4) 2 (7.7)
pT3 (%)   8 (3.4) - - -   8 (30.8)
Lymph node metastasis (%)   3 (1.3) - - -   3 (11.5)
Combined malignancy (%)   65 (27.4) 25 (30.9)   29 (24.8) 6 (46.2)   5 (19.2)
PPPD, pylorus-preserving pancreatoduodenectomy; DP, distal pancreatectomy; HPD, hepatopancreatoduodenectomy; DPRHP, duodenum-preserving resection of the head of the 
pancreas; PHRSD, pancreas head resection with segmental duodenectomy; RM, resection margin. Hwang DW, et al.  •  Scoring Formula for Prediction of Malignant Branch Duct IPMN
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Ethics statement
This study was approved by institutional review board of the 
Seoul National University Hospital (IRB No. H-1007-125-324). 
The board waived the requirement for informed consent. 
 
RESULTS
Malignancy-predicting factors
The subjects were divided into two groups: nonmalignant and 
malignant IPMN. The nonmalignant IPMN group (n = 198) in-
cluded patients with adenomas and borderline tumors, and the 
malignant IPMN group (n = 39) included patients with carcino-
ma in situ and invasive IPMC. On univariate analysis, elevated 
CA 19-9 (P = 0.002), larger cyst size (P < 0.001), the presence of 
mural nodules (P < 0.001), wall thickening (P = 0.036), calcifica-
tion (P = 0.041), and parenchymal atrophy (P = 0.037) were sta-
tistically significant (Table 3). When multivariate analysis was 
performed for these factors, larger cyst size (P = 0.021) and the 
presence of mural nodules (P = 0.001) remained significant 
(Table 4). 
Invasiveness-predicting factors
Adenomas, borderline tumors, and carcinoma in situ were clas-
sified as noninvasive IPMN. Diabetes mellitus (P = 0.036), ele-
vated serum CEA (P = 0.027) or CA 19-9 (P < 0.001), larger cyst 
size (P = 0.001), presence of mural nodules (P < 0.001), wall thick-
ening (P = 0.005), and septation (P = 0.024) were significant vari-
ables on univariate analysis (Table 5). On multivariate analysis, 
elevated CEA (P = 0.043), larger cyst size (P = 0.034), and mural 
nodules (P < 0.001) were statistically significant (Table 6).
Scoring formula for malignancy and invasiveness
The scoring rule was developed using a logistic regression mod-
el with the following form:
  Logit (Y = 1) =   ln (P(Y = 1)/[1-P(Y = 1)]) = b0 + b1X1 + b2X2 + … 
+ bnXn,
  where Y = 1 indicates malignant or invasive IPMN, and ln is 
the natural logarithm. The formula shows that the predictors (X1-
Xn) are linear, and on an additive scale related to the logit (Y = 1), 
with relative weights b1-b2; that is, the regression coefficients. 
This means that, for a particular subject with a certain X1-Xn pro-
file, the regression coefficients multiplied by the patient’s X val-
ues may simply be added to obtain the logit and, by logistic trans-
formation, the probability of Y = 1. Commonly, however, the re-
gression coefficients are multiplied by a number (for instance, 
10) and rounded to the nearest value to easily obtain applicable 
scores per predictor (13).
Malignancy-predicting scores
First, this formula was applied to malignancy-predicting factors. 
The regression coefficient of cyst size was 0.045, and that of mu-
ral nodule presence was 2.237. These coefficients were multi-
plied by 10 and rounded off. Then the formula was constructed 
as follows:
  Malignancy-  predicting score = 22.4 (presence of mural nodule 
[0 or 1]) + 0.5 (size of cyst [mm]).
Table 3. Univariate analysis between nonmalignant and malignant IPMNs
Variables Nonmalignant  
(n = 198)
Malignant  
(n = 39)
P value
Age (yr) 63.0 ± 9.4  63.1 ± 9.2  0.584 
Sex (M:F) 113:85 (1.33:1)  24:15 (1.6:1)  0.606 
Symptom (%) 119 (60.1)  29 (74.4)  0.097 
Combined malignancy (%)   54 (27.3) 11 (28.2) 0.905
CEA, elevated (%)*   6 (3.0)  3 (7.7)  0.133 
CA19-9, elevated (%)
†   20 (10.1)  11 (28.2)  0.002 
Cyst size (mm)   25.0 ± 10.3   36.6 ± 13.8 < 0.001
Mural nodule (%) 17 (8.6)  14 (35.9)  < 0.001 
Wall thickness (mm)   28 (14.1)  11 (28.2)  0.036 
Septation (%)   98 (49.5)  25 (64.1)  0.058 
Calcification (%)   8 (4.0)    5 (12.8)  0.041 
Atrophy (%) 17 (8.6)    8 (20.5)  0.037 
Multifocal lesion (%)   50 (25.3)  15 (38.5)  0.117 
Diffuse distribution   28 (14.1)    9 (23.1)  0.191 
*CEA, elevated; serum level > 5 ng/mL; 
†CA19-9, elevated; serum level > 37 U/mL.
Table 4. Malignancy determining factors by multivariate analysis
Variables Hazard ratio P value 95% confidence  
interval
Cyst size (mm) 1.046  0.021  1.007-1.086 
Mural nodule  9.361 0.001    2.467-35.523
Table 5. Univariate analysis between noninvasive and invasive IPMNs
Variables
Benign + CIS
‡ 
(n = 211)
Invasive carcinoma  
(n = 26) P value
Age (yr) 63.0 ± 9.2  64.1 ± 8.7  0.569 
Sex (M:F) 121:90 (1.34:1)  16:10 (1.6:1)  0.683 
Symptomatic (%) 129 (61.1)  19 (73.1)  0.240 
   Diabetes mellitus   24 (11.4)   7 (26.9) 0.036
Combined malignancy (%)   60 (28.4)   5 (19.2) 0.325
CEA, elevated (%)*   6 (2.8)    3 (11.5)  0.027 
CA19-9, elevated (%)
†   21 (10.0)  10 (38.5)  < 0.001 
Cyst size (mm)   26.2 ± 14.8    43.3 ± 30.5  0.001 
Mural nodule (%) 17 (8.1)  14 (53.8)  < 0.001 
Wall thickness (mm)   29 (13.7)  10 (38.5)  0.005 
Septation (%) 104 (49.3)  19 (73.1)  0.024 
Calcification (%) 10 (4.7)    3 (11.5)  0.191 
Atrophy (%) 20 (9.5)    5 (19.2)  0.166 
Multifocal lesion (%)   56 (26.5)    9 (34.6)  0.495 
Diffuse distribution   31 (14.7)    6 (23.1)  0.336 
*serum level > 5 ng/mL; 
†serum level > 37 U/mL. CIS, carcinoma in situ. 
Table 6. Invasiveness determining factors by multivariate analysis
Variables Hazard ratio P value
95% confidence  
interval
CEA, elevated  24.923    0.043      1.108-560.579 
Cyst size (mm)    1.063    0.034  1.004-1.125 
Mural nodule  38.879 < 0.001      5.364-281.796 Hwang DW, et al.  •  Scoring Formula for Prediction of Malignant Branch Duct IPMN
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  The malignancy-predicting scores were calculated on whole 
subjects based on this scoring formula, and optimal cutoff val-
ues were determined using a receiver-operator characteristic 
(ROC) curve (Fig. 1). The optimal cutoff value was determined 
to be 14, and subjects were divided into two groups: 14 points or 
more, and less than 14 points. Significant differences (P < 0.001) 
were identified between the two groups, with sensitivity of 71.8%, 
specificity of 60.0%, and accuracy of 61.6%.
  These results indicated that branch duct type IPMN with mu-
ral nodule should be regarded as malignant IPMN itself. If pre-
operative CT does not identify mural nodule, cyst size greater 
than 28 mm should be regarded as indicating malignant IPMN.
Invasiveness-predicting scores
Invasiveness-predicting scores were obtained in the same way. 
The regression coefficient of elevated CEA was 3.216, that of cyst 
size was 0.061, and that of mural nodule presence was 3.660. The 
scoring formula was as follows:
  Invasiveness-  predicting score = 36.6 (presence of mural nod-
ule [0 or 1]) + 32.2 (elevated serum concentra-
tion of CEA [0 or 1]) + 0.6 (size of cyst [mm]).
  After calculating the invasive-predicting scores, the best cut-
off value was determined to be 21 points by ROC curve. Based 
on a 21-point cutoff, the two groups were shown to be signifi-
cantly different (P < 0.001) with sensitivity of 76.9%, specificity 
of 72.5%, and accuracy of 73.1% (Fig. 2). These results indicated 
that patients with mural nodule or elevated serum CEA should 
be considered to have invasive IPMN. If the patient had no evi-
dence of mural nodules or elevated serum CEA, cyst size great-
er than 35 mm was regarded as indicating the presence of inva-
sive IPMN.
 
DISCUSSION
Ever since the first report of Ohashi in 1982 (14), asymptomatic 
cystic tumors of the pancreas have been detected with increas-
ing frequency. This has resulted in a dramatic increase in the di-
agnosis of IPMN at specialized centers. Increasing frequency of 
diagnosis is specifically attributed to improved diagnostic tech-
niques, as well as the accumulation of knowledge concerning 
the clinicopathologic characteristics and natural history of spe-
cific IPMN subtypes.
  The management of branch duct type IPMN has proved to be 
complicated. Because branch duct type IPMN has a relatively 
lower risk of malignant or invasive IPMN development, contro-
versy exists regarding the need for surgical resection. The Inter-
national Consensus Guidelines have suggested an algorithm for 
surgical management, which is based on cyst size, patient symp-
toms, and “high risk stigmata” (mural nodules, positive cytolo-
gy). Surgical resection 1) is not recommended in patients with 
branch duct type IPMN < 1 cm, 2) but is recommended in pa-
tients with IPMN in the range of 1 to 3 cm if symptoms, mural 
nodules, or positive cytology are present, and 3) is recommend-
ed in patients with IPMN > 3 cm based on size alone (3, 5). These 
recommendations were based mainly on cyst size, symptoms, 
the presence of mural nodule, and positive cytology. 
  Our study showed similar results in that the presence of mu-
ral nodule and larger cyst size had a statistically significant cor-
relation with malignant and invasive IPMN (5, 9, 15, 16). These 
are the independent criteria used to determine if surgery, and 
specifically radical resection, is needed. Because these factors 
are included into scoring formula, each factor has a statistical 
significance in itself as well as with the others. So, scoring for-
mula is seemed to be complex, but each acts as an independent 
Fig. 1. Receiver operating characteristic (ROC) curve between the malignancy-pre-
dicting score and malignancy. Considering sensitivity and specificity, 14 points was 
the optimal cutoff value.
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Fig. 2. Receiver operating characteristic (ROC) curve of calculated score, related to 
invasiveness. In distinguishing noninvasive IPMN and invasive IPMN, 21 was the most 
reliable cutoff value.
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factor. Thus, in absence of mural nodule, the size of IPMN direct-
ly correlated with the risk of malignancy/invasiveness. If preop-
erative workup reveals the presence of mural nodules or cyst 
size ≥ 35 mm, the lesion should be considered to represent in-
vasive IPMN, and radical resection should be performed. 
  Elevated serum CEA is another independent predictor of in-
vasiveness. Considering that other reports have noted elevated 
serum CEA as a predictor of malignant IPMN, this finding alone 
is enough to indicate the diagnosis (17, 18).
  The results of the present study differ from those of other in-
vestigators’ reports, which have indicated that branch duct type 
IPMN, especially smaller than 30 mm in size, is sufficient cause 
to apply limited resection of the pancreas (8, 19-21). Only 12 of 
32 patients with main duct involvement had cysts larger than 
30 mm in size. Twenty (62.5%) patients with Br-IPMN smaller 
than 30 mm had main duct involvement on pathologic exami-
nation. We did not investigate differences in clinical outcomes 
or prognoses according to the presence of main duct involve-
ment (including recurrence and survival), so we do not know 
the clinical importance of this finding. However, if limited re-
section is intended preoperatively for nonmalignant IPMN, the 
range of resection must be determined very carefully because 
IPMN may involve the main pancreatic duct. The clinical im-
portance of main duct involvement will be investigated in the 
future. 
  In order to determine the necessity of radical resection, the 
likelihood of malignancy and invasiveness must be determined 
on preoperative workup. This is essential to avoid making a di-
agnosis of malignant or invasive IPMN at the postoperative pe-
riod. However, until this time, a formula to predict the risk of 
malignancy and invasiveness for individual patients has not 
been established, and it has been difficult to determine treat-
ment based on preoperative predictions. However, the scoring 
formula based on this study corresponds with clinical data and 
matches a large number of previous papers (7, 9, 22-24).
  Many factors must be considered when determining wheth-
er to operate or observe patients with branch duct type IPMN, 
from general surgical considerations to IPMN-specific ones. Cli-
nicians must be attentive to the presence of mural nodule, the 
elevation of serum CEA, and the size of any cysts. If these actions 
are undertaken, the scoring formula for this study can be applied 
in decision-making. Additional studies will help confirm the 
validity of our findings. Clinicians should then be able to arrive 
at a firm consensus on the appropriate management of branch 
duct type IPMN.
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In order to determine the necessity of radical resection for branch duct type intraductal papillary mucinous neoplasms (IPMN), the 
likelihood of malignancy and invasiveness must be determined on preoperative workup. This is essential to avoid making a 
diagnosis of malignant or invasive IPMN at the postoperative period. However, until this time, a formula to predict the risk of 
malignancy and invasiveness for individual patients has not been established. The scoring formula based on this study corresponds 
with clinical data and matches a large number of previous papers. We suggest to evaluate the presence of mural nodule, the 
elevation of serum CEA, and the size of any cysts. If these actions are undertaken, the scoring formula for this study can be 
applied in decision-making and be helpful for determining surgical management.